KALA BIO Business Summary

KALA BIO, Inc. (KALA) is a clinical-stage biopharmaceutical company currently operating in a strategic turnaround phase following the late-2025 discontinuation of its lead mesenchymal stem cell secretome (MSC-S) program, KPI-012. Since divesting its commercial portfolio to Alcon in 2022, the company generates no recurring product revenue, instead deriving capital from strategic transactions, equity offerings, and private investment agreements. Its primary business segments have transitioned from active ophthalmic R&D to the evaluation of "strategic alternatives," including potential reverse mergers and asset divestitures. KALA competes for capital and strategic partnerships against firms such as Aldeyra Therapeutics, Kodiak Sciences, and Trevi Therapeutics, where it currently functions as a distressed micro-cap entity focused on corporate survival and recapitalization rather than active drug commercialization. The company’s leadership is currently headed by Avi Minkowitz, who assumed the roles of Chief Executive Officer and Chief Financial Officer in February 2026. Minkowitz brings extensive experience in capital restructuring and distressed asset management, having previously held senior roles at Parkit Enterprise and Leonite Capital. He serves alongside Chairman David E. Lazar, a turnaround specialist known for managing micro-cap reorganizations at firms like NovaBay and OpGen, who remains a primary investor following a $6 million capital injection in December 2025. KALA was co-founded by Dr. Justin Hanes, a renowned Johns Hopkins professor and nanomedicine expert who continues to lead the Scientific Advisory Board. Notable institutional shareholders have historically included SR One Capital Management and Baker Bros. Advisors, though current management is primarily focused on navigating Nasdaq delisting threats and executing a corporate reset.